Jazz Pharmaceuticals plc announced financial results for the third quarter ended September 30, 2014. “We successfully executed on key goals across the business, from strong sales growth of Xyrem, Erwinaze, and Defitelio, to advances in our clinical development programs, and to furtherance of our regulatory efforts in preparation for the planned submission of a new drug application for defibrotide in the US in the first half of 2015,” says Bruce C. Cozadd, chairman and CEO of Jazz Pharmaceuticals plc, in a release. “We’re pleased with the substantial progress we’ve made towards meeting our 2014 goals and creating long-term shareholder value.”
Adjusted net income attributable to Jazz Pharmaceuticals plc for the third quarter of 2014 was $145.8 million, or $2.33 per diluted share, compared to $109.4 million, or $1.78 per diluted share, for the third quarter of 2013.
Total revenues for the third quarter of 2014 were $306.6 million, an increase of 32% over total revenues of $232.2 million for the third quarter of 2013. This increase was driven primarily by net product sales of Xyrem (sodium oxybate) oral solution, Erwinaze/Erwinase (asparaginase Erwinia chrysanthemi), and Defitelio (defibrotide).
Xyrem net sales increased by 33% to $204.3 million in the third quarter of 2014 compared to $153.7 million in the third quarter of 2013. During the third quarter of 2014, the average number of active Xyrem patients increased to 12,050.
And in a recent development, the first patient has enrolled in the Phase 3 clinical trial of Xyrem in pediatric narcolepsy patients with cataplexy.